Mirae Asset Global Investments Co., Ltd. Intellia Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $37.3 Billion
- Q1 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,464 shares of NTLA stock, worth $32,284. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,464
Previous 3,394
2.06%
Holding current value
$32,284
Previous $39,000
38.46%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding NTLA
# of Institutions
344Shares Held
98.4MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$121 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$100 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$89.4 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$42 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$35.4 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $708M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...